Cancer Stem Cell News Volume 9.01 | Jan 15 2020

TOP STORY

Arf1-Mediated Lipid Metabolism Sustains Cancer Cells and Its Ablation Induces Anti-Tumor Immune Responses in Mice

Arf1 ablation in cancer cells induced mitochondrial defects, endoplasmic-reticulum stress, and the release of damage-associated molecular patterns, which recruited and activated dendritic cells at tumor sites. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

SFRP1 in Skin Tumor Initiation and Cancer Stem Cell Regulation with Potential Implications in Epithelial Cancers

Investigators used a skin carcinogenesis model, which showed early tumor initiation in Sfrp1 knockout mice and increased tumorigenic potential of Sfrp1 knockout cancer stem cells. [Stem Cell Reports] Full Article

miRNAs as Radio-Response Biomarkers for Breast Cancer Stem Cells

Researchers studied how ionizing radiation affected the expression of miRNAs related to stemness in different molecular breast cancer subtypes. [Mol Oncol] Abstract | Full Article

Suppressing the Metastatic Properties of the Breast Cancer Cells Using STAT3 Decoy Oligodeoxynucleotides: A Promising Approach for Eradication of Cancer Cells by Differentiation Therapy

The authors designed an oligodeoxynucleotide for targeting of signal transducer and activator of transcription 3 (STAT3) transcription factor which was involved in stemness, and constitutively activated in triple-negative breast cancer. [J Cell Physiol] Abstract

The AHR Pathway Represses TGFβ-SMAD3 Signaling and Has a Potent Tumor Suppressive Role in SHH Medulloblastoma

Aryl hydrocarbon receptor-deficient tumors and cancer-propagating cells grown in vitro showed elevated activation of the TGFβ mediator, SMAD3. [Sci Rep] Full Article

Involvement of Collagen XVII in Pluripotency Gene Expression and Metabolic Reprogramming of Lung Cancer Stem Cells

Through screening the genes involved in glycolysis, scientists identified the downstream targets of collagen XVII that were involved in metabolic reprogramming of lung cancer stem cells. [J Biomed Sci] Full Article

Proteome and miRNome Profiling of Microvesicles Derived from Medulloblastoma Cell Lines with Stem-Like Properties Reveals Biomarkers of Poor Prognosis

Investigators evaluated the proteome and miRNome content of extracellular microvesicles released by highly-aggressive stem-like medulloblastoma cells overexpressing the pluripotent factor OCT4A. These cells displayed enhanced tumor initiating capability and resistance to chemotherapeutic agents. [Brain Res] Abstract

L1CAM Defines the Regenerative Origin of Metastasis-Initiating Cells in Colorectal Cancer

The authors showed that L1CAM⁺ cells in human colorectal cancer have metastasis-initiating capacity, and defined their relationship to tissue regeneration. [Nat Cancer] Full Article | Press Release

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

Drug Repurposing towards Targeting Cancer Stem Cells in Pediatric Brain Tumors

The authors provide a synopsis of the drug repurposing methodologies that have been used in pediatric brain tumors, and they argue how this selective compilation of approaches, with a focus on CSC targeting, could elevate drug repurposing to the next level. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Adaptive and Genentech Partner to Use clonoSEQ^® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients

Adaptive Biotechnologies Corporation announced a multi-year, global diagnostic agreement with Genentech to utilize Adaptive’s next-generation sequencing-based clonoSEQ^® Assay to assess minimal residual disease status in response to venetoclax in the registrational Phase III CRISTALLO study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. [Adaptive Biotechnologies Corporation] Press Release

Positive Final Two-Year Topline Data in Completed DC Vaccine Phase I/II Trial in AML Patients

Medigene AG published topline results from its completed open-label Phase I/II clinical trial of Medigene’s autologous dendritic cell (DC) vaccine in 20 patients with acute myeloid leukemia (AML). The study was conducted at the Oslo University Hospital, Norway. Data were collected shortly after completion of the clinical trial, after 24 months of vaccination and follow-up of all patients. [Medigene AG] Press Release

Florida Cracks Down on Foreign Government Involvement in Research

Florida is launching a statewide investigation into US research exploitation after four University of Florida faculty members and six employees of Moffitt Cancer Center in Tampa failed to disclose ties to foreign programs, reports the Tampa Bay Times. [The Scientist] Editorial

FDA and NIH Let Clinical Trial Sponsors Keep Results Secret, Investigation Shows

For 20 years, the US government has urged companies, universities, and other institutions that conduct clinical trials to record their results in a federal database, so doctors and patients can see whether new treatments are safe and effective. [STAT News] Editorial

Protect India’s Universities

For several weeks the world has watched as India’s citizens – including academics and students – have taken to the streets. Tens of thousands have been gathering to read out the preamble to the Indian constitution, as a mark of protest against a discriminatory new citizenship law. [Nature News] Editorial

NEW 2^nd Epigenetics Conference
February 28-March 2, 2020
Nassau, Bahamas

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

NEW Postdoctoral Fellow – Cancer Biology (Oklahoma Medical Research Foundation)

Team Leader – Clonal Evolution in Leukemia (Institute of Cancer Research)

Research Fellow – Glioblastoma Cell Signaling (University of Sussex)

Postdoctoral Associate – Leukemia and Brain Tumors (Ann and Robert H. Lurie Children’s Hospital of Chicago)

Postdoctoral Position – Glioma and Neurodevelopment (Mount Sinai)

Postdoctoral Scholarship – Brain Tumor Stemness (Lund University)

Research Associate – Cell Communication in Tumor Microenvironments (The University of Cambridge)

Postdoctoral Research Scholar – Cancer Biology and Stem Cells (Washington University School of Medicine)

Postdoctoral Fellow – Molecular Diagnostics and Experimental Therapeutics (City of Hope)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.